Sividon Diagnostics Receives Equity Funding
The company intends to use the funds to develop and market innovative invitro diagnostics.
Led by managing directors Dr. Christoph Petry and Dr. Georg Kox, Sividon is launching the EndoPredict® assay for pathology laboratories, which allows a significantly improved risk assessment of breast cancer. The company is also focusing on developing further products in breast cancer and other oncological indications out of its well-filled pipeline.
Sividon is a spin-off from the diagnostics division of Siemens Healthcare.